Baker McKenzie advised Chord Therapeutics (Chord) and its shareholders on the sale of all the shares in Chord to Merck KGaA (Merck). The acquisition is subject to regulatory clearances. This strategic acquisition will enable Merck
Tags :Chord Therapeutics
The team was led by Guy Vermeil (pictured) and included David Ledermann and Federico Trabaldo Togna (all Corporate, M&A), Floran Ponce (Tax), Sevan Antreasyan (Intellectual Property) and Prisca Cattaneo (Employment).
